A-PHP
α-pyrrolidinohexiophenone
Viewing r1 — Apr 28, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
α-PHP (α-pyrrolidinohexanophenone) is a synthetic stimulant of the pyrovalerone cathinone class. It is the direct chain-extended homolog of α-PVP ("flakka"), distinguished by its longer duration of action. α-PHP is a dopamine and norepinephrine reuptake inhibitor, producing its effects by blocking the clearance of these neurotransmitters from the synapse.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
cocaine, α-PVP, MDPV +2 morecocaine, α-PVP, MDPV, amphetamine, methamphetamine show less
The pyrrolidinophenone scaffold was patented in 1967 but never developed pharmaceutically.[3] α-PHP appeared on the Japanese illicit market in 2014 as a scheduling-evasion successor to α-PVP.[4] It was placed under UN Schedule II in 2020 and US DEA Schedule I in 2021.[5]
Subjective effects include intense euphoria, psychomotor activation, wakefulness, and compulsive redosing. The experience is a pure dopaminergic stimulant arc — focused energy and drive without empathogenic warmth — distinguished from shorter-acting relatives by residual stimulation persisting well beyond the subjective peak. Paranoid ideation, hallucinations, agitation, and prolonged insomnia are characteristic unsought effects.
α-PHP carries high abuse liability — preclinical models rate its reward-circuit activation as equivalent to cocaine[6] — with cardiovascular toxicity including rapid heart rate and muscle breakdown.[7] The estimated 37-hour half-life means both stimulant effects and toxic symptoms persist far longer than most stimulants, and psychotic episodes can last days.[8] No clinical trials exist; understanding rests on in vitro pharmacology, animal studies, and clinical case reports.
History[edit]
Discovery
The pyrrolidinophenone scaffold — the chemical backbone of α-PHP — was synthesized and patented in the United States in 1967 as part of a series of potential pharmaceutical agents, but no compound in the series reached clinical development.[3] The ancestor compound, pyrovalerone, had been developed in the 1960s as a treatment for chronic fatigue and was subsequently placed under UN Schedule IV. The hexanophenone variant remained unstudied until a close structural analog (MPHP) appeared in a 2011 poisoning case, establishing that this branch of the family could produce significant stimulant toxicity.[9]
Market emergence
α-PHP first appeared on the Japanese illicit drug market in 2014, following the international wave of attention to α-PVP ("flakka").[4] Its emergence followed a well-established pattern: extending the alkyl chain by one carbon to produce a legal alternative when the predecessor is scheduled.[10] The compound was subsequently identified in intoxication cases across Europe through Swedish surveillance[11] and German forensic casework.[12]
Scheduling and current status
The WHO Expert Committee on Drug Dependence recommended Schedule II placement in 2019, effective internationally in 2020.[3][13] The US DEA issued temporary Schedule I placement in July 2019, followed by permanent classification in July 2021.[5] Research has intensified since scheduling, with the largest clinical case series (29 confirmed cases) published in 2023[12] and the first sex-stratified pharmacokinetic study in 2025.[7]
The designation PV7 follows a pyrovalerone series convention counting carbon backbone length from the ketone carbon — PV5 for α-PVP, PV7 for α-PHP. The "alpha" prefix denotes substitution at the α-carbon adjacent to the ketone, shared across the entire pyrrolidinophenone family. α-PHP's positional isomer α-PiHP — identical molecular formula with a branched rather than straight alkyl chain — was separately scheduled under UN Schedule II in 2023, underscoring the regulatory challenge posed by this rapidly evolving cathinone series.
Chemistry[edit]
Structural class
α-PHP belongs to the pyrovalerone subclass of synthetic cathinones. The molecule consists of a phenyl ring attached via a carbonyl group to an α-carbon bearing both a pyrrolidine ring (a five-membered nitrogen-containing ring) and an n-butyl chain. Its IUPAC name is 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one.[13]
α-PHP is the direct one-carbon chain extension of α-PVP, replacing the n-propyl chain with n-butyl. This structural change is pharmacologically significant: extending the α-alkyl chain enhances both dopamine and NET inhibition within the pyrovalerone series.[1][14]
Molecular properties
| Molecular formula | C₁₆H₂₃NO |
| Molecular weight | 245.36 g/mol |
The compound is a crystalline solid or powder in its hydrochloride salt form.[3] No published data exist for melting point, solubility, or logP — significant characterization gaps. Pyrrolidine-containing cathinones including α-PHP show higher resistance to degradation in biological samples than other cathinone subtypes, with acidified specimens showing substantially improved stability.[4]
Stereochemistry
α-PHP has one chirality center at the α-carbon, producing R- and S-enantiomers. It circulates as a racemic mixture; no enantiopure preparations have been reported in forensic casework. By analogy with α-PVP, where the S-enantiomer is approximately 125-fold more potent at the DAT than the R-enantiomer, significant enantioselective differences in activity are expected but have not been formally characterized.[2]
Structure-activity relationships
A systematic study of ring substitutions on the α-PHP scaffold found that most 4-position substituents (fluorine, chlorine, bromine, methyl, methoxy) maintain dopamine transporter potency within a narrow range, with strong selectivity for dopamine over serotonin transporters.[15] The trifluoromethyl structural analog was a notable outlier, showing approximately 80-fold reduced potency and loss of transporter selectivity.[15] These findings indicate that α-PHP's unsubstituted phenyl ring sits near the potency optimum for this scaffold.
Pharmacology[edit]
Mechanism of action
α-PHP blocks the dopamine transporter (DAT) and norepinephrine transporter (NET), preventing these neurotransmitters from being cleared from the synapse.[2][16][3] This is a pure reuptake inhibitor mechanism — pharmacologically analogous to cocaine and MDPV rather than amphetamine-type drugs, which force neurotransmitters out of nerve terminals.[2][17]
The dopamine blockade produces euphoria, focused energy, and psychomotor drive. The norepinephrine blockade drives peripheral effects — rapid heart rate, elevated blood pressure, dilated pupils — and central arousal. α-PHP shows no meaningful activity at the SERT,[1][2] distinguishing it from empathogenic cathinones like mephedrone and explaining the absence of serotonergic warmth in its effect profile.
No precise potency measurement has been published for α-PHP specifically, though it is described as "at least as potent as α-PVP" at the DAT.[15] It does not release monoamines — it only blocks their reuptake.[1]
Pharmacokinetics
The only human pharmacokinetic data come from a single case report: a 39-year-old male presenting with psychosis had an initial serum concentration of 175 ng/mL, with an estimated elimination half-life of 37 hours.[8] This exceptionally long half-life — far exceeding cocaine (approximately 1 hour) or amphetamine (10–12 hours) — means the compound persists in the body for days after a single dose. Psychotic symptoms in this case resolved by day 3, consistent with the slow clearance.
In a larger forensic series of 29 confirmed cases, serum concentrations ranged from 1 to 83 ng/mL.[12] Animal studies found that male mice achieved higher plasma levels than females at the same dose, yet females showed greater behavioral sensitivity — including stronger locomotor, tactile, and temperature responses — suggesting sex-dependent differences in how the drug reaches or acts in the brain.[7]
Metabolism
α-PHP is metabolized in the liver through multiple cytochrome P450 enzymes, primarily CYP1A2 and CYP2C19.[14] The main metabolic routes include modification of the pyrrolidine ring, ring-opening reactions, and alkyl chain breakdown. In human urine, 11 primary metabolites and 5 glucuronide conjugates have been identified, with dihydroxy-pyrrolidinyl-α-PHP proposed as the primary urinary biomarker.[12][18]
The parent compound shows no direct mutagenicity, but metabolites generated through liver processing demonstrated mutagenic potential in laboratory assays.[19] This suggests that genotoxicity risk may come from breakdown products rather than α-PHP itself.
Neuroscience[edit]
Where it acts
By blocking dopamine reuptake in the nucleus accumbens and related reward circuits, α-PHP floods these regions with dopamine — the signal the brain uses to mark experiences as rewarding and worth repeating. Parallel norepinephrine elevation in prefrontal circuits drives the arousal, vigilance, and sympathetic activation that accompany the high.
Preclinical studies confirm this directly: α-PHP lowered brain reward thresholds in rats at levels comparable to cocaine, a validated measure of reward circuit activation and abuse potential.[6] Locomotor stimulation in female rats further confirms central dopaminergic drive.[20]
Why it matters
α-PHP's pharmacology maps onto the incentive salience framework — the distinction between wanting (motivational drive toward reward) and liking (hedonic pleasure). Selective dopamine potentiation preferentially amplifies wanting, which may explain the compulsive redosing characteristic of pyrovalerone cathinones: the urge to re-dose intensifies even as subjective pleasure diminishes.
Repeated exposure to dopamine reuptake inhibitors also produces competing neuroadaptations — behavioral sensitization (escalating motor responses) alongside tolerance to euphoria — a dual process that drives the cycle of stimulant dependence.
In vitro studies show α-PHP kills neural stem cells at high concentrations through multiple cell death pathways,[21] but tested concentrations far exceed measured human blood levels. Whether chronic exposure at realistic concentrations damages the brain's neurogenic regions remains unknown.
Subjective Effects[edit]
The α-PHP experience is a pure dopaminergic stimulant arc — intense euphoria, sharpened focus, and driven wakefulness without the empathogenic warmth or prosocial quality of serotonergic cathinones. Route of administration shapes the experience dramatically: smoked or vaporized α-PHP delivers a brief, intense rush that strongly promotes compulsive redosing, while oral administration produces a slower build. At higher doses or with repeated administration, the focused stimulation tips into paranoid ideation, hallucinations, and agitated psychosis. Set and setting significantly modulate this trajectory.
The experiential character is most comparable to α-PVP and cocaine — sharing the focused euphoria of potent dopamine reuptake inhibitors — but with a far longer tail. Where cocaine cycles in 30–60 minutes and α-PVP in 2–4 hours, α-PHP's residual stimulation, insomnia, and dysphoria extend the commitment to a day or more.
Effect Grid
At common doses, the full stimulant experience is present: pronounced euphoria with a strong dopaminergic rush, marked psychomotor activation, thought acceleration, and intense focus. Confidence and sociability increase substantially. Music appreciation is enhanced. A sense of purpose and drive dominates the cognitive landscape.
Cardiovascular effects become significant — tachycardia, elevated blood pressure, and sweating are typical. Appetite is strongly suppressed. Jaw tension and bruxism may emerge. Body temperature rises.
Compulsive redosing urges become prominent at this range. The long half-life (estimated 37 hours) means effects persist well beyond the subjective peak, and sleep is impossible for many hours. Functional impairment is substantial.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Touch enhancement · Brightness alteration · Peripheral misidentification · Auditory distortion · Visual drifting · Visual acuity suppression · Auditory misinterpretation · Touch suppression · Auditory hallucinations · Shadow people · External hallucinations
Visual drifting · Visual acuity suppression · Auditory misinterpretation · Touch suppression · Auditory hallucinations · Shadow people · External hallucinations
Restlessness · Insomnia · Pupil dilation · Dry mouth · Excessive sweating · Body high · Heart rate perception changes · Muscle tension · Physical fatigue · Headache · Bruxism · Dehydration sensation · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Trembling · Nausea · Involuntary body movements · Sexual arousal enhancement · Dizziness · Nasal congestion · Respiratory stimulation · Abnormal heartbeat · Increased urination · Constipation · Nystagmus (eye wobbles) · Vomiting · Seizure threshold reduction · Tactile hallucination
Dry mouth · Excessive sweating · Body high · Heart rate perception changes · Muscle tension · Physical fatigue · Headache · Bruxism · Dehydration sensation · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Trembling · Nausea · Involuntary body movements · Sexual arousal enhancement · Dizziness · Nasal congestion · Respiratory stimulation · Increased urination · Constipation · Nystagmus (eye wobbles) · Vomiting · Seizure threshold reduction · Tactile hallucination
Thought deceleration · Motivation suppression · Cognitive dysphoria · Focus suppression · Focus enhancement · Motivation enhancement · Analysis enhancement · Information processing suppression · Immersion enhancement · Aesthetic enhancement · Cognitive impairment · Information processing enhancement · Multiple thought streams · Thought loops · Confusion · Delusions of sobriety · Memory fragmentation · Pattern recognition enhancement · Thought disorganization · Creativity enhancement · Delusions · Delirium
Focus suppression · Focus enhancement · Motivation enhancement · Analysis enhancement · Information processing suppression · Immersion enhancement · Aesthetic enhancement · Cognitive impairment · Information processing enhancement · Multiple thought streams · Thought loops · Confusion · Memory fragmentation · Pattern recognition enhancement · Thought disorganization · Creativity enhancement · Delusions · Delirium
Anhedonia · Dysphoria · Emotional lability · Mania
Communication enhancement · Sociability enhancement · Social connection · Flow state · Automaticity · Depersonalization · Derealization
Automaticity · Depersonalization · Derealization
Timeline
First alerts emerge as mild wakefulness and subtle mood elevation. A slight increase in heart rate may be perceptible.
Stimulation builds progressively — euphoria, mental clarity, and psychomotor activation develop over 30–60 minutes. Heart rate and blood pressure begin to rise.
Maximum dopaminergic stimulation: intense euphoria, pronounced thought acceleration, strong motivation, and marked psychomotor activation. Cardiovascular effects (tachycardia, hypertension) are most pronounced. Compulsive redosing urges are strongest during and immediately after this phase.
Euphoria diminishes while stimulation persists. Residual wakefulness, restlessness, and appetite suppression continue. The gap between wanting to redose and actual pleasure widens.
Gradual return toward baseline, though the long elimination half-life means residual stimulation, insomnia, and mild cardiovascular elevation can persist for many hours. Irritability and dysphoria may emerge.
Residual effects may persist for 12–48 hours given the 37-hour serum half-life: lingering insomnia, appetite suppression, fatigue, and low mood.
⚠ Do not drive or operate machinery until after a full night of restorative sleep, which may not be achievable for 24 hours or more after dosing.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- cocaine · α-PVP · MDPV
Toxicity
Acute toxicity
No lethal dose has been established for α-PHP. No animal lethality studies exist, and no published case documents a human death from α-PHP alone — all documented fatalities involved multiple substances.
The acute toxic presentation includes agitation, hallucinations, paranoid delusions, rapid heart rate, elevated blood pressure, rapid breathing, high body temperature, and muscle breakdown.[7][12][8] Psychosis lasting 3 or more days has been documented, consistent with the compound's long half-life.[8]
Cardiovascular effects
Rapid heart rate, elevated blood pressure, and rapid breathing are consistently reported.[7] Closely related pyrovalerone cathinones (MDPV, α-PVP) have produced abnormal heart rhythms, dangerously high blood pressure, and heart attacks, though these specific outcomes have not been directly reported for α-PHP.inferred
Muscle breakdown
Muscle breakdown (rhabdomyolysis) is documented in α-PHP intoxications.[7] This condition releases muscle proteins into the bloodstream and can cause acute kidney damage, requiring intravenous fluids and kidney function monitoring.
Neurotoxicity
Laboratory studies show α-PHP kills neural stem cells at high concentrations through multiple cell death pathways.[21] These concentrations are 35- to 2,800-fold higher than the maximum measured human blood level, and the clinical relevance to human exposure is uncertain.
Genotoxicity
α-PHP itself shows no direct mutation-causing activity, but liver-generated metabolites demonstrated mutagenic potential in laboratory assays.[19]
Reproductive toxicity
A fetal death has been associated with maternal use of α-PHP and MDPHP.[22] In utero transfer is confirmed — two neonates tested positive via meconium.[12]
Psychological Risks
Stimulant psychosis — hallucinations, paranoid ideation, and delusions — is the most prominent acute psychological risk. In one documented case, psychosis persisted for 3 days.[8] The 37-hour half-life means psychotic episodes can last far longer than those produced by shorter-acting stimulants.
Agitation, aggressive behavior, and impaired judgment are consistently reported.[12][7] The combination of paranoia, agitation, and physical activation creates risk of self-harm and violence during acute intoxication.
Tolerance & Dependence
α-PHP has high abuse liability. Preclinical models rate its reward-circuit activation as equivalent to cocaine,[6] and animal self-administration shows reinforcement comparable to cocaine and methamphetamine.[3] Abuse liability is assessed as equivalent to α-PVP.[20]
The WHO Expert Committee on Drug Dependence concluded that α-PHP's mechanism "suggests it is highly likely to produce a state of dependence similar to amphetamine".[3] The dopamine reuptake inhibitor mechanism is "probably associated with a considerable risk of addiction".[2]
No controlled human studies on tolerance development or dependence formation exist. Cross-tolerance with other dopamine reuptake inhibitors (cocaine, MDPV, α-PVP) is expected but has not been directly demonstrated.
Drug Interactions
90% of confirmed cases in the largest clinical series involved multiple substances simultaneously.[12] The most common co-intoxicants were opiates (60%), benzodiazepines (35%), cannabinoids (30%), and cocaine (20%).
Opioid co-use is the most common real-world combination. Stimulant-opioid combinations mask opioid sedation, increasing overdose risk when the stimulant wears off and respiratory depression is unmasked. α-PHP's unusually long half-life changes the timing of this danger compared to cocaine-opioid combinations.
Tramadol co-use carries multiple risk vectors: additive cardiovascular stress from combined norepinephrine reuptake inhibition, lowered seizure threshold from both drugs independently, and tramadol's serotonergic activity creating potential for adrenergic crisis.safety citation needed
MDMA co-use would produce additive dopamine and norepinephrine activation via complementary mechanisms, substantially elevating cardiovascular stress and overheating risk.safety citation needed
MAO inhibitors are an absolute contraindication for all dopamine/norepinephrine reuptake inhibitors: combined blockade of breakdown and reuptake creates risk of dangerously high blood pressure crisis.inferred
α-PHP is not detected by standard drug screens,[23] requiring specialized laboratory testing for identification. This complicates emergency treatment, particularly when multiple substances are involved.
Clinical management follows pyrovalerone cathinone protocols: supportive care with benzodiazepines for agitation and seizure prevention, intravenous fluids for muscle breakdown, and cardiovascular and temperature monitoring.[24]
Contraindications
Pre-existing heart conditions — including high blood pressure, coronary artery disease, and irregular heartbeat — represent the primary absolute contraindication.[7]
Psychotic spectrum disorders and bipolar disorder are absolute contraindications: α-PHP's dopamine potentiation directly worsens psychotic symptoms, and documented multi-day psychosis[8] makes episodes potentially severe and prolonged.
Pregnancy is absolutely contraindicated: fetal death has been documented,[22] and the compound crosses to the fetus.[12]
MAO inhibitor use is an absolute contraindication.inferred
Seizure disorders are a relative contraindication: stimulant cathinones lower seizure threshold as a class effect.
Concurrent use of other dopamine/norepinephrine-active stimulants (cocaine, amphetamines, MDPV) produces additive cardiovascular and neuropsychiatric risk.
Harm Reduction[edit]
Forms & Identification
α-PHP is not detected by standard immunoassay drug screens,[23] meaning standard workplace or hospital urine tests will not identify it. Confirmatory identification requires specialized laboratory methods. Because synthetic cathinones are frequently mislabeled or substituted for one another on unregulated markets, reagent testing helps verify identity but cannot confirm purity or dose. Quantitative analysis is not available to most users, making precise dosing from unverified material inherently uncertain.
Guidelines
- Test all material with reagent kits before use
- Weigh doses with a milligram-precision scale — never estimate by eye
- Set a firm dose limit before beginning and separate any remaining material from the session space
- Use the oral route for slower onset and reduced compulsive redosing compared to smoking or vaporizing
- Ensure access to water, food, and a cool environment to manage body temperature and hydration
- Schedule the session with at least 24–36 hours of recovery time afterward, including sleep
- Avoid redosing — the long half-life means subsequent doses stack on residual drug, escalating cardiovascular strain and psychosis risk
- Have benzodiazepines available for emergency agitation management if accessible and appropriate
Set & Setting
α-PHP's dopaminergic selectivity and long half-life create specific environmental considerations. The compound's strong drive toward compulsive redosing means that having additional material accessible during a session significantly increases the risk of escalating use. Pre-measure a single dose and store or remove any remaining supply before beginning.
The 37-hour half-life means committing to potential insomnia and residual stimulation lasting well beyond the desired experience — plan for at least 24 hours of affected function. A trusted, sober companion who can recognize paranoid ideation or agitation provides a critical safety check, particularly because the user may lack insight into their own deteriorating mental state.
Aftercare & integration. The primary recovery need after α-PHP use is sleep. The 37-hour half-life means residual stimulation and insomnia may persist for 1–2 days after last use. Do not fight this with additional stimulants — the body needs uninterrupted rest.
Eat regular meals even without appetite. Hydrate consistently. Expect a mood crash — dopamine depletion following intense reuptake blockade produces low mood, fatigue, and loss of interest that may last several days. Physical activity, social contact, and routine help restore baseline faster than isolation. If paranoid thoughts, hallucinations, or severe anxiety persist beyond 72 hours after last use, seek medical evaluation — prolonged psychosis is documented with this compound and may require clinical intervention.
Recovery & Support
α-PHP's high abuse liability and compulsive redosing pattern mean that repeated use can rapidly escalate to dependence. The dopaminergic mechanism produces cravings and reward-seeking behavior similar to cocaine and methamphetamine dependence.
Professional support options include addiction medicine specialists, cognitive behavioral therapy, and peer support groups experienced with stimulant dependence. No pharmacological treatment specific to synthetic cathinone dependence exists, but approaches effective for cocaine and amphetamine dependence are applicable. Crisis resources include SAMHSA's National Helpline (1-800-662-4357) and local poison control centers.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Seek immediate help for chest pain, seizure, loss of consciousness, body temperature hot to the touch through clothing, sustained aggressive or incoherent behavior, or psychosis with self-harm risk. Severe agitation with inability to sit still, rapid breathing, and confusion indicate serious toxicity.
Immediate steps:
- Call emergency services immediately
- Move the person to a cool, quiet environment
- Remove objects that could cause injury if agitation is present
- Do not physically restrain unless there is immediate danger to self or others
- Offer water if the person can drink safely
- Monitor breathing and consciousness until help arrives
What to tell the dispatcher: Name the substance (α-PHP or synthetic cathinone), estimated amount and time of use, current symptoms, and whether other substances were taken. Good Samaritan laws in many jurisdictions protect callers from prosecution — calling for help is always the right decision.
Clinical management follows pyrovalerone cathinone protocols: benzodiazepines for agitation and seizure prevention, intravenous fluids for muscle breakdown, and cardiovascular and temperature monitoring.[24]
Legal Status[edit]
α-PHP is internationally controlled under Schedule II of the 1971 UN Convention on Psychotropic Substances, effective 2020, following the WHO Expert Committee on Drug Dependence recommendation in 2019.[3][13] The compound has no recognized therapeutic use and has been classified as a substance of high abuse potential by every evaluating body.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Schedule II, 1971 Convention on Psychotropic Substances | Effective 2020; recommended by 42nd ECDD meeting 2019[3] |
| United States | Schedule I (Controlled Substances Act) | Temporary placement July 18, 2019 (84 FR 34291); permanent placement July 16, 2021[5] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under generic cathinone clausecitation needed |
| Sweden | Narcotic | Classified June 1, 2015; among earliest national scheduling actions[4] |
| Japan | Controlled | First detected on market 2014; controlled under Narcotics and Psychotropics Control Law[4] |
| EU member states | Subject to 1971 Convention obligations | Monitored by EMCDDA Early Warning System; national implementations vary |
| Canada | Controlled (presumed) | Cathinones broadly addressed under CDSA; specific schedule designation not confirmedcitation needed |
| Australia | Controlled (presumed) | Addressed under state/territory NPS legislation and TGA Poisons Standard; specific schedule not confirmedcitation needed |
Analog act considerations
α-PHP's structural relationship to α-PVP and pyrovalerone — both independently scheduled — means it would likely fall under structural analog legislation in jurisdictions employing structural similarity provisions, even without specific scheduling. In the United States, permanent Schedule I placement renders the Federal Analogue Act moot for α-PHP itself, though it remains relevant for novel analogs not yet individually scheduled.
references
- [1] ^abcdKolaczynska KE, Thomann J, Hoener MC, Liechti ME (2021) The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative. — International journal of molecular sciences doi:10.3390/ijms22158277
- [2]
- [3]
- [4]
- [5]
- [6] ^abcBaird TR, Davies RA, Glennon RA, Peace MR, Negus SS (2021) A Strategy to Prioritize Emerging Drugs of Abuse for Analysis: Abuse Liability Testing Using Intracranial Self-Stimulation (ICSS) in Rats and Validation with α-Pyrrolidinohexanophenone (α-PHP) — Emerging Trends in Drugs, Addictions, and Health doi:10.1016/j.etdah.2021.100004